Therapy Areas: Diabetes
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
18 December 2025 - Clywedog Therapeutics Inc, a US-based clinical-stage biotechnology company, announced on Wednesday the activation of all clinical centres and patient dosing in its international Pha...
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
12 December 2025 - Swedish medical technology company Qlife Holding AB (STO: QLIFE), which develops the Egoo Health at-home diagnostics platform, said on Friday that its system will be used in a perfo...
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
8 December 2025 - Diabetes management company ALR Technologies SG Ltd (OTC: ALRTF) announced on Monday that it has completed internal manufacturing testing of its GluCurve Pet CGM, confirming accuracy...
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
27 November 2025 - Chinese biopharmaceutical company Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced on Thursday that it has begun GRADUAL-3, its third large-scale phase 3 study of the...
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
25 November 2025 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Tuesday reported positive phase 2 results for amycretin in people with type 2 diabetes, showing statistical...
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
20 November 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX: 01801) announced on Wednesday that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/gluc...